

Amendment to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of the Claims:

1.-100. (Cancelled)

101. (Currently Amended) A composition which comprises:

- a) a conjugate of (i) ~~a GD3 lactone ganglioside derivative which comprises an unaltered oligosaccharide part and an altered ceramide portion comprising an altered sphingosine base~~ a derivative of a GD3 lactone ganglioside which GD3 lactone ganglioside comprises an unaltered sphingosine base, wherein the derivative differs from the GM2 ganglioside solely by having an altered sphingosine base which retains only C1 through C4 from the unaltered sphingosine base of the GD3 lactone ganglioside, and (ii) Keyhole Limpet Hemocyanin[[]], wherein the GD3 lactone ganglioside derivative is covalently bound to Keyhole Limpet Hemocyanin by a stable amine bond between the C-4 carbon of the altered sphingosine base and a nitrogen of an ϵ -aminolysyl group of Keyhole Limpet Hemocyanin;

b) ~~QS-21 a saponin derivable from the bark of a Quillaja saponaria Molina tree; and~~

c) a pharmaceutically acceptable carrier;

wherein the amount of the conjugated GD3 lactone ganglioside derivative is an amount between about 1 µg and about 200 µg, the amount of QS-21 ~~the saponin~~ is an amount of between about 10 µg and about 200 µg, ~~and~~ the GD3 lactone:Keyhole Limpet Hemocyanin molar ratio is from 200:1 to 1400:1, the relative amounts of such conjugate and ~~such saponin being~~ QS-21 ~~is~~ effective to stimulate or enhance production in a subject of an antibody to the GD3 lactone ganglioside.[[,]]

~~wherein in the conjugate the ganglioside derivative is covalently bound to Keyhole Limpet Hemocyanin through a C-4 carbon of the altered sphingosine base of the altered ceramide portion of the ganglioside derivative to an ε-aminolysyl group of Keyhole Limpet Hemocyanin, wherein the C-4 carbon is present in a CH₂ group; and.~~

102.-107. (Cancelled)

108. (Currently Amended) The composition of claim 101, wherein the amount of QS-21 ~~the saponin~~ is about ~~100~~ 50 µg.

109. (Currently Amended) The composition of claim

101, wherein the amount of QS-21 ~~the saponin~~ is about 200 µg.

110. (Cancelled)

111. (Currently Amended) The composition of claim 101 which comprises:

- a) a conjugate of (i) ~~a GD3 lactone ganglioside derivative which comprises an unaltered oligosaccharide part and an altered ceramide portion comprising an altered sphingosine base~~ a derivative of a GD3 lactone ganglioside which GD3 lactone ganglioside comprises an unaltered sphingosine base, wherein the derivative differs from the GM2 ganglioside solely by having an altered sphingosine base which retains only C1 through C4 from the unaltered sphingosine base of the GD3 lactone ganglioside, and (ii) Keyhole Limpet Hemocyanin[[]], wherein the GD3 lactone ganglioside derivative is covalently bound to Keyhole Limpet Hemocyanin by a stable amine bond between the C-4 carbon of the altered sphingosine base and a nitrogen of an ε-aminolysyl group of Keyhole Limpet Hemocyanin;
- b) ~~QS-21, a saponin derivable from the bark of a Quillaja saponaria Molina tree; and~~

c) a pharmaceutically acceptable carrier;

wherein the amount of the conjugated GD3 lactone ganglioside derivative is ~~present in~~ an amount of between about 1 µg and about 200 µg, the amount of ~~the saponin~~ QS-21 is about 100 µg, and the GD3 lactone:Keyhole Limpet Hemocyanin molar ratio is from 200:1 to 1400:1, and ~~wherein~~ the ~~amount~~ relative amounts of such conjugate and ~~such saponin~~ QS-21 is effective to stimulate or enhance production in a subject of an antibody to the GD3 lactone ganglioside.[[;]]

~~and wherein in the conjugate the ganglioside derivative is covalently bound to Keyhole Limpet Hemocyanin through a C-4 carbon of the altered sphingosine base of the altered ceramide portion of the ganglioside derivative to an ε-aminolysyl group of Keyhole Limpet Hemocyanin, wherein the C-4 carbon is present in a CH₂ group; and.~~

112. (Currently Amended) A method of treating a subject afflicted with melanoma which comprises administering to said subject an amount of the composition of claim 111 effective to stimulate or enhance production of an antibody to the GD3 ganglioside in the subject and to thereby treat said melanoma in said subject.

113. (Currently Amended) A method of stimulating or enhancing production of an antibody to the GD3

lactone ganglioside in a subject which comprises administering to the subject an effective amount of a composition which comprises:

- a) a conjugate of (i) ~~a GD3 lactone ganglioside derivative which comprises an unaltered oligosaccharide part and an altered ceramide portion comprising an altered sphingosine base~~ a derivative of a GD3 lactone ganglioside which GD3 lactone ganglioside comprises an unaltered sphingosine base, wherein the derivative differs from the GM2 ganglioside solely by having an altered sphingosine base which retains only C1 through C4 from the unaltered sphingosine base of the GD3 lactone ganglioside, and (ii) Keyhole Limpet Hemocyanin[[]], wherein the GD3 lactone ganglioside derivative is covalently bound to Keyhole Limpet Hemocyanin by a stable amine bond between the C-4 carbon of the altered sphingosine base and a nitrogen of an ϵ -aminolysyl group of Keyhole Limpet Hemocyanin;
- b) QS-21 ~~a saponin derivable from the bark of a Quillaja saponaria Molina tree;~~ and
- c) a pharmaceutically acceptable carrier;

wherein the amount of the conjugated GD3 lactone

ganglioside derivative is an amount between about 1 μ g and about 200 μ g, the amount of ~~the saponin~~ QS-21 is an amount between about 10 μ g and about 200 μ g, ~~and~~ the GD3 lactone:Keyhole Limpet Hemocyanin molar ratio is from 200:1 to 1400:1, and the relative amounts of such conjugate and ~~such saponin being~~ QS-21 is effective to stimulate or enhance production on a subject of an antibody to the GD3 lactone ganglioside.[[,]]

~~wherein in the conjugate the ganglioside derivative is covalently bound to Keyhole Limpet Hemocyanin through a C-4 carbon of the altered sphingosine base of the altered ceramide portion of the ganglioside derivative to an ϵ -aminolysyl group of Keyhole Limpet Hemocyanin, wherein the C-4 carbon is present in a CH_2 group, so as to thereby stimulate or enhance production in the subject of the antibody to GD3.~~

114. (Currently Amended) A method of treating a human subject having cancer which comprises administering to the subject an effective amount of a composition which comprises:

- a) a conjugate of (i) ~~a GD3 lactone ganglioside derivative which comprises an unaltered oligosaccharide part and an altered ceramide portion comprising an altered sphingosine base~~ a derivative of a GD3 lactone ganglioside which GD3

lactone ganglioside comprises an unaltered sphingosine base, wherein the derivative differs from the GM2 ganglioside solely by having an altered sphingosine base which retains only C1 through C4 from the unaltered sphingosine base of the GD3 lactone ganglioside, and (ii) Keyhole Limpet Hemocyanin[[]], wherein the GD3 lactone ganglioside derivative is covalently bound to Keyhole Limpet Hemocyanin by a stable amine bond between the C-4 carbon of the altered sphingosine base and a nitrogen of an ϵ -aminolysyl group of Keyhole Limpet Hemocyanin;

- b) QS-21 ~~a saponin derivable from the bark of a Quillaja saponaria Molina tree; and~~
- c) a pharmaceutically acceptable carrier;

wherein the amount of the conjugated GD3 lactone ganglioside derivative is an amount between about 1 μ g and about 200 μ g, the amount of ~~the saponin~~ QS-21 is an amount of between about 10 μ g and about 200 μ g, ~~and~~ the GD3 lactone:Keyhole Limpet Hemocyanin molar ratio is from 200:1 to 1400:1, the relative amounts of such conjugate and ~~such saponin~~ QS-21 is being effective to stimulate or enhance production in a subject of an antibody to the GD3 lactone ganglioside,

~~wherein in the conjugate the ganglioside derivative is covalently bound to Keyhole Limpet Hemocyanin through a C-4 carbon of the altered sphingosine base of the altered ceramide portion of the ganglioside derivative to an ϵ -aminolysyl group of Keyhole Limpet Hemocyanin, wherein the C-4 carbon is present in a CH₂ group, so as to thereby stimulate or enhance production of an antibody to CD3 in the subject and thereby treat the cancer.~~

115. (Previously Presented) The method of claim 114, wherein the cancer is of epithelial origin.
116. (Previously Presented) The method of claim 114, wherein the cancer is of neuroectodermal origin.
117. (Currently Amended) The method of claim 116, wherein the cancer of neuroectodermal origin is a melanoma.
118. (Previously Presented) The method of claim 113 or 114, wherein the administering is effected at two or more sites.
119. (Previously Presented) The method of claim 118, wherein the administering is effected at three sites.
120. (Previously Presented) The method of claim 113 or 114, wherein the composition is administered subcutaneously to said subject.

121. (Previously Presented) The method of claim 120, wherein the composition is administered to said subject at two-week intervals.
122. (Previously Presented) The method of claim 120, wherein the composition is initially administered to said subject at weekly intervals.
123. (Currently Amended) The method of claim 113 or 114, wherein the composition to be administered is prepared prior to administration to the subject by mixing the conjugate and QS-21 ~~the saponin~~.
124. (Currently Amended) The method of claim 123, wherein the conjugate and QS-21 ~~the saponin~~ are mixed on the day of administration to the subject.
125. (Cancelled)